Paredox Therapeutics LLC Company Profile, Contacts & Intelligence

Paredox Therapeutics LLC Overview

Paredox Therapeutics is currently developing novel therapeutics which modulate mitochondrial pathways that drive diseases of oxidative stress. Our lead program is currently focused on malignant pleural mesothelioma. Over the past several years, two academic research teams working via sponsored research agreements with Paredox have developed the key proof-of-concept, pre-clinical data demonstrating the ability of the therapy to significantly reduce tumor burden in mice harboring malignant mesothelioma tumors. Collaborative work between the laboratories has determined the molecular mechanism for inhibition of the principle antioxidant pathway in mitochondria and the ability of the lead compound to irreversibly inactivate this pathway. Research to-date has identified key features of the compounds, targets and cellular environment that significantly influence specificity and efficacy. Importantly, this protein target is dysregulated in most cancer types. Thus, inhibition of the protein has broad applicability and therapeutic potential for cancer therapy. Most notably treatments using this unique MOA can be guided by a companion diagnostic identifying patients with sufficiently dysregulated metabolic pathways prone to respond to therapy. RS Oncology is also dedicated to the development of a bio-marker which can result in a companion diagnostic test. Paredox envisions a disease-agnostic approach (treat the biomarker not the disease) in treating patients with this novel therapeutic approach.

Headquarters

No.2 Minster Court

Website

paredoxtherapeutics.com

Industry

Biotechnology

Founded

2017

Compare Similar Companies to Paredox Therapeutics LLC

Explore companies in related markets and compare their industry and employee estimates.